Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

No Thumbnail Available
Authors
Mujica-Mota, R.
Varley-Campbell, J.
Tikhonova, I.
Cooper, C.
Griffin, E.
Haasova, M.
Peters, J.
Lucherini, S.
Talens-Bou, J.
Long, L.
Journal
Health technology assessment (Winchester, England)
Type
Journal Article
Systematic review
Publisher
NIHR
Rights
Archived with thanks to Health technology assessment (Winchester, England)
Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system.
Citation
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. 2018, 22 (49):1-326 Health Technol Assess
Note
This report is freely available online. Click on the link above to access the full-text